Statins #brief_notes تجميعة مفيدة لنسب تقليل الكوليسترول الضار بعد الأدوية
🧠 High-intensity statin therapy is expected to lower LDL-C levels by ≥50%,
🧠 moderate-intensity statin therapy by ≥30% to 49%
🧠 low-intensity statin therapy by <30%
.
🧠 Statin therapy lowers TG 10% to 30% in a dose-dependent manner
.
🧠 Ezetimibe lowers LDL-C levels by a mean of 18% (25% incremental reduction when added to statin therapy) and has a low incidence of side effects
.
🧠 PCSK9 monoclonal antibodies (mAbs) can lower LDL-C by 45% to 64%, are well tolerated and safe,5,6 and reduce ASCVD events in patients at very-high risk when added to statin therapy.
🧠 Inclisiran, a small-interfering ribonucleic acid (RNA)-based PCSK9i, lowers LDL-C by 48% to 52%, and is well tolerated with several CVOT currently in progress
.
🧠 Bempedoic acid, an adenosine triphosphate citrate lyase inhibitor, lowers LDL-C by 21% to 24% as monotherapy in patients with statin-attributed side effects, and by an additional 17% to 18% in combination with a maximally tolerated statin
.
🧠 Nonstatins in combination with low- or moderate-intensity statin therapy can produce ≥50% LDL-C reduction
.
🧠 Olezarsen is a novel antisense oligonucleotidebased apo C-III inhibitor that is approved for Familial chylomicronemia syndrome (FCS).
.
🧠 Given the breadth of CVOT evidence, statins remain first-line therapy for patients with TG ≥500 mg/dL to reduce ASCVD risk even though they reduce TG less than fibrates or omega-3 fatty acids.
.
